Pavel Raifeld, Innoviva CEO
February 2, 2022 11:08 AM ESTUpdated 11:24 AM
Deals

Cash-strapped an­tibi­otics play­er En­ta­sis could go pri­vate with a small-dol­lar buy­out of­fer on the ta­ble

Amber Tong

It looks like an­tibi­otics play­er En­ta­sis may be get­ting off Nas­daq the same way it ar­rived — with a whim­per.

En­ta­sis

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Rare dis­ease bio­phar­ma com­pa­nies weigh in on FDA's new in­no­va­tion hub

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times